- Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS (including COVID-19 ARDS)
- Kyowa Kirin Co. has an option to retain the rights for all indications in Japan
-
Welcome to Crohn's Forum, a support group for people with all forms of IBD. While this community is not a substitute for doctor's advice and we cannot treat or diagnose, we find being able to communicate with others who have IBD is invaluable as we navigate our struggles and celebrate our successes. We invite you to join us.
Cerecor Announces License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
- Thread starter asadmom
- Start date